ab-729
Nucleic acidexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2021 (NCT04847440)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis B virusANTISENSE INHIBITOR
Hepatitis B virus antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314644 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06245291 | Phase 2 | May 1, 2024 | Arbutus Biopharma Corporation |
| NCT06154278 | Phase 2 | Dec 1, 2023 | Arbutus Biopharma Corporation, University of Maryland |
| NCT04980482 | Phase 2 | Oct 29, 2021 | Arbutus Biopharma Corporation |
| NCT04820686 | Phase 2 | May 7, 2021 | Arbutus Biopharma Corporation, Assembly Biosciences |
| NCT04847440 | Phase 2 | Mar 30, 2021 | Antios Therapeutics, Inc |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arbutus Biopharma Corporation | For profit | 4 | 2 | 1 | 2021 |
| Antios Therapeutics, Inc | For profit | 1 | 1 | 1 | 2021 |
| Assembly Biosciences | For profit | 1 | 1 | 1 | 2021 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1